Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Although the SPAC craze was (re)ignited in 2020, the volume of SPAC activity hit all?time time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Faced with depressed venture funding activity (which for digital health declined nearly 50% from 2021 ), an uncertain IPO market and pressure to provide liquidity to investors, M&A offered digital health startups a solution to deliver liquidity, streamline costs and bridge funding gaps as they continue to develop their products.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. It is also likely that IPOs will come to PPM, perhaps first to those specialties with the largest assets (e.g.,

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64